文献速递泌尿男性生殖肿瘤

非转移性前列腺癌临床预后分期系统的开发与验证

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
PubMed 文献 · JAMA Oncol · 2020-01-01

验证集10年PCSM从0.3%至40.0%,C指数0.796优于AJCC第8版(0.757),也优于NCCN和CAPRA分组。

要点

  • Score系统预测10年PCSM范围0.3%-40.0%,区分度C指数0.796优于AJCC第8版0.757。
  • 在年龄、种族、治疗方式及SEER验证队列中,Score系统均表现更优。
  • Score系统优于NCCN三分组(0.729)和四分组(0.746)及CAPRA(0.760)。

核心结论

  • 利用大型国际队列开发了符合AJCC要求的非转移性前列腺癌临床预后分期系统。

主要发现

  • 验证集中9个Score组的预测10年PCSM范围为0.3%至40.0%。
  • 10年C指数为0.796(95%CI 0.760-0.828),高于AJCC第8版的0.757(95%CI 0.719-0.792)。
  • Score系统在年龄、种族和治疗方式亚组中均改善区分度,并在SEER验证队列中一致。
  • Score系统优于NCCN三分组(10年C指数0.729)和四分组(0.746)以及CAPRA(0.760)。

关键数值与推荐

  • 纳入变量包括年龄、T分期、N分期、Gleason分级、治疗前血清PSA水平及阳性穿刺针数百分比。
  • 验证集中9个Score组的10年PCSM预测值从0.3%到40.0%。
  • Score系统10年C指数0.796(95%CI 0.760-0.828),AJCC第8版为0.757(95%CI 0.719-0.792)。

临床怎么用

  • 该Score系统可用于非转移性前列腺癌的临床预后分期,辅助临床决策和临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In 2016, the American Joint Committee on Cancer (AJCC) established criteria to evaluate prediction models for staging. No localized prostate cancer models were endorsed by the Precision Medicine Core committee, and 8th edition staging was based on expert consensus. OBJECTIVE: To develop and validate a pretreatment clinical prognostic stage group system for nonmetastatic prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This multinational cohort study included 7 centers from the United States, Canada, and Europe, the Shared Equal Access Regional Cancer Hospital (SEARCH) Veterans Affairs Medical Centers collaborative (5 centers), and the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry (43 centers) (the STAR-CAP cohort). Patients with cT1-4N0-1M0 prostate adenocarcinoma treated from January 1, 1992, to December 31, 2013 (follow-up completed December 31, 2017). The STAR-CAP cohort was randomly divided into training and validation data sets; statisticians were blinded to the validation data until the model was locked. A Surveillance, Epidemiology, and End Results (SEER) cohort was used as a second validation set. Analysis was performed from January 1, 2018, to November 30, 2019. EXPOSURES: Curative intent radical prostatectomy (RP) or radiotherapy with or without androgen deprivation therapy. MAIN OUTCOMES AND MEASURES: Prostate cancer-specific mortality (PCSM). Based on a competing-risk regression model, a points-based Score staging system was developed. Model discrimination (C index), calibration, and overall performance were assessed in the validation cohorts. RESULTS: Of 19 684 patients included in the analysis (median age, 64.0 [interquartile range (IQR), 59.0-70.0] years), 12 421 were treated with RP and 7263 with radiotherapy. Median follow-up was 71.8 (IQR, 34.3-124.3) months; 4078 (20.7%) were followed up for at least 10 years. Age, T category, N category, Gleason grade, pretreatment serum prostate-specific antigen level, and the percentage of positive core biopsy results among biopsies performed were included as variables. In the validation set, predicted 10-year PCSM for the 9 Score groups ranged from 0.3% to 40.0%. The 10-year C index (0.796; 95% CI, 0.760-0.828) exceeded that of the AJCC 8th edition (0.757; 95% CI, 0.719-0.792), which was improved across age, race, and treatment modality and within the SEER validation cohort. The Score system performed similarly to individualized random survival forest and interaction models and outperformed National Comprehensive Cancer Network (NCCN) and Cancer of the Prostate Risk Assessment (CAPRA) risk grouping 3- and 4-tier classification systems (10-year C index for NCCN 3-tier, 0.729; for NCCN 4-tier, 0.746; for Score, 0.794) as well as CAPRA (10-year C index for CAPRA, 0.760; for Score, 0.782). CONCLUSIONS AND RELEVANCE: Using a large, diverse international cohort treated with standard curative treatment options, a proposed AJCC-compliant clinical prognostic stage group system for prostate cancer has been developed. This system may allow consistency of reporting and interpretation of results and clinical trial design.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dess RT, Suresh K, Zelefsky MJ, et al. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020. PMID: 33090219. doi:10.1001/jamaoncol.2020.4922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。